<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82908">
  <stage>Registered</stage>
  <submitdate>19/06/2008</submitdate>
  <approvaldate>25/07/2008</approvaldate>
  <actrnumber>ACTRN12608000364370</actrnumber>
  <trial_identification>
    <studytitle>Enhanced Influenza Vaccines in Chronic Disease Study</studytitle>
    <scientifictitle>Randomized, controlled Phase 1/2 study to evaluate the safety and effectiveness of an enhanced potency adjuvanted seasonal influenza vaccine in patients with chronic disease and the elderly</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>FLU002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart disease</healthcondition>
    <healthcondition>Chronic Obstructive Pulmonary Disease</healthcondition>
    <healthcondition>Diabetes Mellitus</healthcondition>
    <healthcondition>Chronic renal disease</healthcondition>
    <healthcondition>Old age</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Other public health</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose of Advax-adjuvanted (20 miligram) seasonal 2008 trivalent inactivated influenza vaccination (total 45 micrograms of haemagglutinin) given once only by intramuscular injection</interventions>
    <comparator>Single dose of seasonal 2008 trivalent inactivated influenza vaccination (total 45 micrograms of haemagglutinin) given once only by intramuscular injection</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Immunogenicity as assessed by haemagglutination inhibition assay (HAI)</outcome>
      <timepoint>3-4 weeks post vaccination</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety as assessed by local (e.g. injection site reactions including pain, swelling, erythema) and systemic adverse events (e.g. fever, nausea, myalgia) as recorded in subject diaries and routine biochemical and haematological screening assays</outcome>
      <timepoint>3 weeks post vaccination</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Influenza-related morbidity as assessed by incidence of respiratory infections, hospitalisations and unscheduled general practitioner  or emergency department visits need for antibiotic therapy.</outcome>
      <timepoint>3, 6, and 12  months post vaccination</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of chronic obstructive pulmonary disease, diabetes mellitus, cardiovascular disease or chronic renal disease or age 60 years or greater</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History of vaccination with current (2008) season influenza vaccine, History of vaccine or egg allergy, Women of childbearing potential unless using a reliable and appropriate contraceptive method, specifically oral contraceptive pill, intrauterine device or mechanical barrier device, Pregnant or lactating women, Concurrent immunosuppressive therapy, including corticosteroids (with the exception of topically applied/inhaled steroids), Individuals with a known infection of human immunodeficiency virus (HIV), History of intravenous drug abuse or alcohol abuse</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/04/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vaxine pty Ltd</primarysponsorname>
    <primarysponsoraddress>Flinders Medical Centre
Adelaide 5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Vaxine Pty Ltd</fundingname>
      <fundingaddress>Flinders Medical Centre
Adelaide 5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study seeks to determine whether the effectiveness of current flu vaccines in protecting people with chronic disease against flu-complications can be improved by addition of a specific compound (adjuvant) which acts by boosting the immune response to the vaccine</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Flinders Clinical Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre
Adelaide 5042</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Nikolai Petrovsky</name>
      <address>Flinders Medical Centre
Adelaide 5042</address>
      <phone>0882044572</phone>
      <fax />
      <email>nikolai.petrovsky@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Dimitar Sajkov</name>
      <address>Flinders Medical Centre
Adelaide 5042</address>
      <phone>0882044572</phone>
      <fax />
      <email>dimitar.sajkov@fmc.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Nikolai Petrovsky</name>
      <address>Flinders Medical Centre
Adelaide 5042</address>
      <phone>0882044572</phone>
      <fax>0882045987</fax>
      <email>nikolai.petrovsky@flinders.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>